Filgotinib Maleate

Phase 3

Eisai

Filgotinib Maleate is one of 46 therapeutic programs targeting Ulcerative Colitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ulcerative ColitisActive, not recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

91 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Phase 3

10 2

Skyrizi

AbbVie

Phase 3

6 3

Jyseleca

Gilead

Phase 3

6 4

Humira

RRanbaxy Laboratories Limited

Phase 3

19 5

Velsipity

Pfizer

Phase 3

10 6

Mesalazine

Ferring

Phase 3

17 7

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 8

Jardiance

Boehringer Ingelheim

Phase 2

2 9

Atorvastatin Calcium

Merck & Co.

Phase 2

1 10

Zasocitinib

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedActive, not recruiting

Ulcerative Colitis

NCT06964113

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Active, not recruiting· Eisai logo

Eisai·Approved·NCT06964113·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Filgotinib Maleate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Filgotinib Maleate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Eisai

Filgotinib Maleate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News